Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveEnzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinomaImmunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cellsChemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.Basic principles and technologies for deciphering the genetic map of cancer.Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Synergistic effects of nanosecond pulsed electric fields combined with low concentration of gemcitabine on human oral squamous cell carcinoma in vitro.PharmGKB summary: gemcitabine pathwaySLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro studyClinical pharmacology and pharmacogenetics of gemcitabine.Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.Novel strategy with gemcitabine for advanced pancreatic cancer.Antimetabolite Treatment for Pancreatic Cancer.Chemotherapy-induced toxicity is highly heritable in Drosophila melanogasterAcquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.Curcumin Induces Pancreatic Adenocarcinoma Cell Death Via Reduction of the Inhibitors of ApoptosisAldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.Noninvasive prediction of tumor responses to gemcitabine using positron emission tomographyGemcitabine in the treatment of metastatic pancreatic cancer.Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.Pancreatic adenocarcinoma: new strategies for successEnhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer.SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Pharmacogenomics in bladder cancer.Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-κB.Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.
P2860
Q26752368-40B7300F-3537-408D-9C98-7D86A9705513Q29616287-2879C43D-0DF9-4798-BA69-205A6830FC6FQ30238470-C601AA88-9D6D-4CB8-A0E4-3EB463CF9406Q33385281-BC265994-2ED4-4190-BE41-61CB207D40F8Q33395417-33C7577D-5D16-44E9-8D0D-23A059972B78Q33575608-AE9A670E-197D-469D-83D0-444768813BC8Q33591937-AB708DCD-B3BC-4173-B6A9-3DC0DAE92FABQ33670961-135F153F-92C0-44E5-B425-227424FE5D7FQ33889319-B3ED9402-6947-4B7D-9A2F-7F632CDF267EQ34074628-F3EC916C-7581-481E-8C1D-53A396372ACCQ34205171-BDEDEDF5-3DC8-4BDF-91BD-117420A35CB8Q34254837-13C43327-6786-4DBC-8740-8E7D8416C618Q34395614-BC69565B-4F19-4207-8BB5-313A54A4511BQ34435450-98087C7D-28BE-4968-8568-3BED879267E6Q34528361-F423FD6B-659B-4E2B-B746-DBCE5D99CCA9Q34985979-5297893D-9879-4C88-8707-6294B670F16CQ35130652-5CC51022-CA95-4598-B203-9B095FDEEB1AQ35432223-00EF11AB-DE91-40B4-9AB5-74052297F886Q35826334-0B2639AC-6A12-4303-B6A5-AD435A1B55A2Q35830711-A6EFD1FD-3569-4C93-8CAB-F4BC311F1108Q35870211-0A2E2310-73F3-433B-8114-46CE726671ECQ35909171-EEF9270D-A6CF-4F94-B113-D8810E31E09FQ36201693-E8481A86-9E9A-434A-8851-C754AE019A37Q36302124-B3FED979-1B66-4703-B01B-00CB236C5EE4Q36373429-C7429BF6-2370-4646-B49D-3B6023FB3F68Q36429978-7F4CC759-A987-4E45-A1E4-D961632D9E79Q37066064-E8AEF998-F14F-41FE-A327-EA8A26982943Q37085729-B4A7EB15-7B06-40CD-A7B7-F15925E7DD85Q37134412-CD89C98D-F187-4B0C-9042-1F605163142BQ37141957-D28C5076-A086-4DD5-888F-3A93BE4C3A21Q37198628-95BCF3CF-6C8C-4543-9B8B-962B997E21ADQ37440160-BC1A0CFF-4E43-4982-B348-6817835E1069Q37507420-C8A3368F-01D3-4732-A17E-A70987068632Q37523551-26488CED-574D-4AA4-A5EB-0325782BF933Q37593002-1DB0FF74-FF70-47E9-8112-25BBC106A75AQ37876401-0546A289-D277-4034-9B1F-CB3790F755C5Q37955222-B3E8A8FA-90AF-410A-B8CE-980EF35B9D26Q38058785-49B7481F-6BDA-468C-9CBE-5F8AC78B3899Q38461595-CAB46FBD-50DA-41A6-812D-5E028E0785A6Q38835169-D464226D-063C-4846-8AFF-A968EAE9473B
P2860
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
@ast
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
@en
type
label
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
@ast
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
@en
prefLabel
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
@ast
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
@en
P2093
P2860
P921
P356
P1476
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603860
P407
P577
2007-06-26T00:00:00Z
2007-07-16T00:00:00Z